T Bafana

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

JA Thompson, Cissy Kityo, David Dunn, Anne Hoppé et autres

gb, Ouganda, ca, Zimbabwe, Malawi, es, sg (code pays fourni par la source)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, JA Thompson, Cissy Kityo, Anne Hoppé et autres

Zimbabwe, gb, Ouganda, Malawi, Kenya, Zambie, sg (code pays fourni par la source)

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nicholas I. Paton, Leonard Bagenda, Joep J. van Oosterhout, Silvia Bertagnolio et autres

sg, gb, Ouganda, Zimbabwe, Malawi, ch (code pays fourni par la source)

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda

Ruth Goodall, David Dunn, Theresa Pattery, Anja Van Cauwenberge et autres

gb, Ouganda, Nigéria, au (code pays fourni par la source)

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

Ravindra K. Gupta, Ruth Goodall, Michael Rañopa, Cissy Kityo et autres

gb, Ouganda, au, Afrique du Sud, fr (code pays fourni par la source)

Prevention of HIV-1 Infection with Early Antiretroviral Therapy for the HPTN 052 Study Team*

Myron S. Cohen, Ying Qing Chen, Marybeth McCauley, Theresa Gamble et autres